Capital Fund Management (CFM)
RCUS icon

Capital Fund Management (CFM)’s Arcus Biosciences RCUS Stock Holding History

Capital Fund Management (CFM)’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-64,809
Closed -$987K – 2121
2024
Q2 		$987K Buy
64,809
+51,233
+377% +$827K ﹤0.01% 1608
2024
Q1 		$256K Buy
+13,576
New +$235K ﹤0.01% 1931
2022
Q3 		– Sell
-96,224
Closed -$2.44M – 1608
2022
Q2 		$2.44M Buy
+96,224
New +$2.36M 0.02% 765

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital Fund Management (CFM)'s RCUS Position: Q3 2024 in Review

Capital Fund Management (CFM) sold out of Arcus Biosciences (RCUS) in Q3 2024, closing a stake of 64,809 shares — an estimated $987K sold.

Capital Fund Management (CFM) first reported a position in RCUS in Q2 2022 and held it in 3 quarters. The position peaked at $2.44M in Q2 2022. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2024.

  • Capital Fund Management (CFM) reported no remaining Arcus Biosciences position as of Q3 2024 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 64,809 Arcus Biosciences shares in Q3 2024, an estimated $987K.
  • Capital Fund Management (CFM) first reported a position in Arcus Biosciences in Q2 2022 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s Arcus Biosciences position peaked at $2.44M in Q2 2022.
  • 187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2024.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2024, filed 13 Nov 2024.